



1614

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.

Dated: April 2, 2007

Signature: (Mary Jane DiPalma)

Docket No.: GPCI-P02-191
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bockovich et al.

Application No.: 10/584,485

Confirmation No.: 3055

Filed: June 23, 2006

Art Unit: 1614

For: INHIBITORS OF CYCLIN-DEPENDENT
KINASES, COMPOSITIONS AND USES
RELATED THERETO

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. GPCI-P02-191. A duplicate copy of this paper is enclosed.

Dated: April 2, 2007

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735
FISH & NEAVE IP GROUP, ROPES & GRAY
LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	10/584,485
				Filing Date	June 23, 2006
				First Named Inventor	Nicholas Bockovich
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	GPCI-P02-191


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA	US-2,989,583		06-20-1961	Flores et al.	
AB	US-3,211,731		10-12-1965	Schmidt et al.	
AC	US-3,211,732		10-12-1965	Schmidt et al.	
AD	US-5,593,356		01-14-1997	Takeda	
AE	US-5,593,997		01-14-1997	Dow et al.	
AF	US-6,291,504		09-18-2001	Nugiel et al.	
AG	US-6,407,103		06-18-2002	Nugiel et al.	
AH	US-6,413,957		07-02-2002	Nugiel et al.	
AI	US-2001/0027195		10-04-2001	Nugiel et al.	
AJ	US-2003/0165873		09-04-2003	Come et al.	
AK	US-2004/0043388		03-04-2004	Come et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
BA	WO-94/13677		06-23-1994		
BB	WO-98/05335		02-12-1998		
BC	WO-99/54308		10-28-1999		
BD	WO-00/21926		04-20-2000		
BE	WO-02/067654		09-06-2002		
BF	WO-02/070662		09-12-2002		
BG	WO-02/093269		11-21-2002		
BH	WO-02/34721		05-02-2002	Du Pont Pharm Co	
BI	WO-02/40182		05-23-2002		
BJ	WO-02/44174		06-06-2002		
BK	WO-03/004491		01-16-2003		
BL	WO-03/033499		04-24-2003	GPC Biotech Inc.	
BM	WO-03/063764		08-07-2003		
BN	EP-0203679		12-03-1986		
BO	JP-60-130521		07-12-1985	Toshiyasu	
BP	JP-62-099361		05-08-1987	Yoshio, et al	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Mosher et al., "Benzene Ring Substituted Indeno[1,2-c]pyrazol-4(1H)-ones," J. Org. Chem. 35(11):3685-3688 (1970)			

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/584,485
				Filing Date	June 23, 2006
				First Named Inventor	Nicholas Bockovich
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	GPCI-P02-191

	CB	Nugiel et al., "Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors," J. Med. Chem. 44:1334-1336 (2001)	
	CC	Nugiel et al., "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern," J. Med. Chem. 45:5524-5232 (2002)	
	CD	Yue et al., "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3. Structure Activity Relationships at C3 (1,2)," J. Med. Chem. 45:5233-5248 (2002)	
	CE	Shaw et al., "Purines, Pyrimidines and Imidazoles...," Chemical Abstracts Abstract No. 5837, 75(1) (1971)	
	CF	"Protein Kinase Targets: Strategies for Drug Development," Conference Presentation June 10-11, 2003 Westin Copley Place Hotel, Boston, MA	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--